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ABSTRACT
Background: Despite the availability of hundreds of cancer drugs, there is
insufficient data on the efficacy of these drugs on the extremely heterogeneous tumor
cell populations of glioblastoma (GBM).
Results: The PKIS of 357 compounds was initially evaluated in 15 different
GSC lines which then led to a more focused screening of the 21 most highly active
compounds in 11 unique GSC lines using HTS screening for cell viability. We further
validated the HTS result with the second-generation PLK1 inhibitor volasertib as a
single agent and in combination with ionizing radiation (IR). In vitro studies showed
that volasertib inhibited cell viability, and high levels of the anti-apoptotic protein BclxL expression were highly correlated with volasertib resistance. Volasertib sensitized
GSCs to radiation therapy by enhancing G2/M arrest and by inducing apoptosis. Colonyformation assay demonstrated that volasertib plus IR synergistically inhibited colony
formation. In intracranial xenograft mouse models, the combination of volasertib and
radiation significantly inhibited GSC tumor growth and prolonged median survival
compared with radiation treatment alone due to inhibition of cell proliferation,
enhancement of DNA damage, and induction of apoptosis.
Conclusions: Our results reinforce the potential therapeutic efficacy of volasertib
in combination with radiation for the treatment of GBM.
Methods: We used high-throughput screening (HTS) to identify drugs, out of 357
compounds in the published Protein Kinase Inhibitor Set, with the greatest efficacy
against a panel of glioma stem cells (GSCs), which are representative of the classic
cancer genome atlas (TCGA) molecular subtypes.
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INTRODUCTION

RESULTS

Glioblastoma (GBM) is the most common and
aggressive form of primary brain tumors in adults.
Current therapy for GBM, using a combination
of surgery, radiation, and chemotherapy, reduces
intracranial tumor burden with modest efficacy in
prolonging survival [1]. Patients with GBM have a mean
survival of 12 to 14 months from the time of diagnosis,
with fewer than 5% of patients alive at 3 years [1, 2].
Despite the availability of hundreds of cancer drugs,
there are limited treatment options for patients, and there
is insufficient information on the efficacy of these drugs
in the extremely heterogeneous populations of tumor
cells in GBM [3].
GBM displays striking intratumoral heterogeneity
and a high resistance to radiation and chemotherapy, due
to the presence of stem-like glioma stem cells (GSCs),
also called glioma tumor-initiating cells (GSCs). GSCs
have the ability to undergo self-renewal and initiate
tumorigenesis, and they are resistant to a wide variety
of chemotherapeutic agents and possess a remarkable
ability to recover from cytotoxic therapy [4, 5]. The
advent of high-throughput screening (HTS) has enabled
the screening of large, diverse compound libraries
against a panel of cells to validate targets and identify
drug candidates for clinical development [6]. Therefore,
integration of comprehensive HTS of molecularly
targeted agents with patient-derived GSCs that have been
extensively profiled by multiple “omics” techniques,
such as genomics, methylomics and proteomics, provides
an extraordinary opportunity to develop targeted
therapies for subsets of patients with GBM [7]. In this
study, HTS was used to identify drug sensitivities to 357
compounds in the published Protein Kinase Inhibitor
Set (PKIS) from GlaxoSmithKline (GSK) using a panel
of GSCs, which are representative of the classic cancer
genome atlas (TCGA) molecular subtypes [8] and are
highly characteristic of human glioma growth patterns
that contribute to tumor initiation and therapeutic
resistance. From the initial 357 compounds, the 21 most
highly active compounds were more extensively studied.
This HTS screen identified sensitivity of GSCs to
inhibitors of polo-like kinase-1 (PLK1), a key regulator
of mitosis [9]. Given that PLK1 is often overexpressed
in a broad spectrum of cancers, with highest expression
levels being correlated with poor prognosis in several
cancer types [10–13], we further validated the HTS result
with the second-generation PLK1 inhibitor volasertib
(BI6727, Boehringer Ingelheim, Germany) as a single
agent and in combination with ionizing radiation (IR).
Here, we describe, for the first time, the in vitro and in
vivo efficacy of volasertib as a single agent and combined
with radiation in GSCs.

High-throughput screening of published PKIS
compounds against GSCs identifies PLK1 as a
potential therapeutic target for glioblastoma

www.impactjournals.com/oncotarget

Two PKIS compound libraries were obtained from
GlaxoSmithKline, and both compound libraries have
been tested for kinase activity. The compound structure
and PKIS data are readily available at ChEMBL [14, 15].
The PKIS of 357 compounds was initially evaluated on
15 different cell lines of GSCs (data not shown) which
led to a more focused screening of the 21 most highly
active compounds in 11 unique cell lines of GSCs
(Supplementary Table 1). We used an IC50 of < 1 µM
as a cutoff for sensitivity of each compound. We used
the IC50 cutoff values given that they demonstrated a
good correlation with area under the curve (AUC) and
because IC50 provides a dose reference for further in vitro
and in vivo experiments (Supplementary Table 2). The
heatmap depicting the IC50 of 21 compounds against the 11
GSC lines is shown in Figure 1. Of these 21 compounds,
we found 8 compounds with potent inhibition of cell
viability in at least 10 GSC lines; however, some of these
compounds demonstrated potent activity at nanomolar
concentrations against a large number of kinases, creating
challenges in determining mechanism of action. In
contrast, 10 compounds showed little or no cytotoxicity
against at least 10 GSC lines. Furthermore, only two
compounds (GSK978744A and GW301789X) showed
statistically significant association to TCGA subtypes
(Supplementary Table 3) but without having any GSCs
sensitive to these compounds. Interestingly, our HTS data
showed that 2 GSC lines had IC50 < 1 µM, 8 GSC lines had
IC50 ranging from 1 to 5 µM, and 1 GSC line had IC50 >
5 µM for GSK579289A; whereas for GSK317315A,
1 GSC line had IC50 < 1 µM, 8 GSC lines had IC50 ranging
from 1 to 5 µM, and 2 GSC lines had IC50 > 5 µM.
GSK579289A and GSK317315A have been tested
for kinase inhibitory activity, and both selectively and
potently inhibit PLK1 (96% inhibition for GSK579289A,
97% inhibition for GSK317315A) at a low concentration
(100 nM) [14, 15]. In summary, our HTS assay of PKIS
compounds against a panel of GSC lines indicated that
PLK1 is a potential therapeutic target of GBM.

Inhibition of PLK1 by volasertib results in cell
cycle arrest and apoptosis in GSCs
PLK1 is often overexpressed in a broad spectrum
of cancers, including GBM (proteinatlas.org), and high
PLK1 expression levels correlate with poor prognosis.
We further verified our HTS results by testing the
second-generation PLK1 inhibitor volasertib on GSCs.
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We tested 27 GSC lines to determine their sensitivity
to volasertib and found that volasertib inhibited cell
viability with an IC50 ranging from 7.72 nM to 11.4 µM
(data not shown). Moreover, we correlated proteomic
RPPA data with volasertib responses of 27 GSC subtypes
to find predictors of drug sensitivity. Figure 2A shows a
heatmap from the top 20 significant proteins correlated to
volasertib sensitivity based on a distinct protein expression
pattern among sensitive and resistant GSCs. Among these
proteins, high expression of anti-apoptotic Bcl-2 family
protein was highly correlated with volasertib resistance
(P < 0.00033, Figure 2A), suggesting apoptosis contributed
to the antitumor activity of volasertib. Consistent with
this finding, treatment with volasertib induced prominent
poly ADP ribose polymerase cleavage (c-PARP) in a
dose-dependent and time-dependent manner (Figure 2B),
suggesting volasterib treatment led to substantial induction
of apoptosis in GSCs. In addition, Supplementary Figure 1
shows that Volasertib response has not association with a
specific TCGA subtype indicating that Volasertib is a good
candidate for clinical trials independent of tumor subtype.

PLK1 is a critical regulator of cell cycle progression
[13, 16]. To investigate the effects of volasertib on GSC
cell cycle distribution, we subjected GSCs to three different
concentrations (1 nM, 10 nM, and 100 nM) of volasertib for
different times (16, 24, and 48 hours) and then, measured
the cell cycle by flow cytometry (Supplementary Figure 2).
We observed a dose- and time-dependent increase in cells in
G2/M phase, as well as a sub-G1 accumulation after longer
exposure to volasertib, indicating that volasertib abrogates
mitosis followed by induction of apoptosis. These data are
consistent with our results showing volasertib-mediated
PARP cleavage and results observed by others in HeLa
cells, HUVECs and NSCLC [17].

PLK1 inhibition by volasertib enhances the
radiosensitivity of GSCs by modulating cell cycle
arrest
Given previous findings that radiosensitivity of cells
is dependent on the phase of the cell cycle [18, 19], with
cells in S phase being the most radioresistant and cells in

Figure 1: An HTS assay was used to identity drug sensitivities of 21 compounds in the PKIS (GSK) in a panel of 11
GSC lines, which were representative of the classic cancer genome atlas (TCGA) molecular subtypes. Heatmap, depicting
the IC50 of these compounds, identified PLK1 as a therapeutic target of GSC.

www.impactjournals.com/oncotarget
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Volasertib synergistically enhances the sensitivity
to radiation by apoptosis induction, DNA
damage, and inhibition of colony formation

G2/M the most radiosensitive, we examined the combined
effect of volasertib and radiation on cell cycle arrest.
Representative and group data of cell cycle distribution,
shown in Figure 3, demonstrated that inhibition of PLK1
with volasertib resulted in a dose-dependent G2/M arrest
and polyploidy production in GSCs. Polyploidy can be
induced by persistent DNA damage signaling [20, 21], and
cells unable to undergo mitosis (i.e, mitotic catastrophe)
can demonstrate polyploidy. Therefore, our data suggest
that volasertib led to DNA damage and to induction of
mitotic catastrophe in GSCs. Combining volasertib with
2 Gy of radiation additively enhanced G2/M arrest and
polyploidy production. These findings are consistent
with previous reports showing that PLK1 inhibition with
GSK461364A in U87 and U251 GBM [22] and with
BI2536 in medulloblastoma cells [23] induced mitotic
catastrophe and enhanced radiosensitivity.

To further determine whether PLK inhibition
enhances the sensitivity of GSCs to radiation, we subjected
GSCs to different concentrations of volasertib for 24
hours followed by 2 Gy of radiation. Forty-eight hours
after radiation, cleaved PARP was significantly greater in
the combination treatment group than in the volasertibtreatment alone group (Figure 4A, Supplementary
Figure 3). Consistent with the induction of apoptosis in the
combination treatment group, there was a corresponding
decreased expression of anti-apoptotic protein Bcl-xL and
an increase expression of pro-apoptotic protein Bad. Similar
findings were observed with respect to γ-H2AX, an index
of DNA damage [24], which was significantly higher at 48

Figure 2: The HTS result was further verified in vitro with the second-generation PLK1 inhibitor volasertib. (A)

Heatmap from the top ranked 20 proteins associated to Volasertib sensitivity; anti-apoptotic Bcl-2 family proteins were the most significant.
Correlation of the volasertib IC50 with fold-change (log2) in protein expression in 27 GSC lines demonstrated that high expression levels
of anti-apoptotic Bcl-2 family proteins were a predictor of resistance to volasertib. (B) Whole-cell protein extracts were analyzed after
different time points of treatment with different concentrations of volasertib and GSK461364 by Western blot, with the indicated antibodies.
Representative Western blot data demonstrated that volasertib induced prominent c-PARP in a dose- and time-dependent manner, indicating
that inhibition of PLK1 resulted in apoptosis in a time- and dose-dependent manner.
www.impactjournals.com/oncotarget
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hours following radiation compared with the corresponding
volasertib-treatment alone group. We further analyzed
apoptosis by flow cytometry measurement of annexin
V-propidium iodide staining. As shown in Figure 4B,
there was no significant difference in apoptosis 48 hours
after radiation compared with control; however, necrosis
(as indicated by propidium iodide-positive staining) was
higher in the radiation-treatment alone group. In contrast,
apoptosis induction was significantly higher in the cells
that received 100 nM volasertib plus 2 Gy of radiation than
in the volasertib-treatment alone group. Taken together,
these data suggest that the cytotoxic effects of combining
volasertib and radiation are primarily mediated through
apoptosis induction.
We performed the clonogenic (or colony-forming)
assay, a widely used standard for evaluating radiation
sensitivity of different cell lines in vitro, to determine
the effects of volasertib on colony-forming ability and

compared it with and without radiation. The average
percentage of colony formation of post-irradiated GSCs
was significantly lower compared to control, both in
GSC23 (68.33% ± 0.95% versus 97.20% ± 1.10%,
P < 0.01) and in GSC272 (96.13% ± 0.57% versus 88.9%
± 1.10%). Moreover, volasertib treatment at sub-IC50 doses
(1 nM and 10 nM) resulted in a significant decrease in
colony formation, which was further reduced by radiation
treatment (Figure 4C). Together, our data demonstrated
that the combination of volasertib and radiation
synergistically inhibited colony formation in vitro.

Combined volasertib and radiation
synergistically inhibits tumor growth and
prolongs median survival in vivo
We further examined the combined effect of volasertib
and radiation on intracranial xenograft models of GSCs.

Figure 3: G2/M arrest induced by volasertib was additively enhanced by radiation. GSCs were subjected to 2 Gy of ionizing

radiation after 24 hours of treatment with volasertib, and then cell cycle distribution was analyzed 48 hours after radiation. Representative
(A) and group (B) data of cell cycle distribution demonstrated that volasertib and radiation had an additive effect on G2/M arrest, in a dosedependent manner. Shown are representative data from three individual experiments.

www.impactjournals.com/oncotarget
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One week prior to initiating IR, volasertib (10 mg/kg) was
administrated twice a week until the end of the experiment
clinically relevant, fractionated IR (2.5 Gy × 4) was applied
to mice 3 weeks after intracranial implantation of GSCs.
As expected, mice that received GSC272 (Figure 5A) and
GSC23 (Figure 5E) showed significantly improved median
survival upon IR treatment alone compared to untreated
controls, with median survival prolonged from 62.5 days to
83.5 days, and 68 days to 81 days respectively. Importantly,
the combination of volasertib with IR treatment significantly
improved median survival compared with IR alone in
mice transplanted with GSC272 (89 days versus 68 days,
P < 0.001) and with GSC23 (90 days versus 83.5 days,
P < 0.001). Most importantly, 30% of the mice that received
combination treatment demonstrated long-term survival
(sacrificed at 104 days without moribund syndrome),
whereas 0% of mice survived in the other treatment groups.
In addition, H&E staining of combination-treated brains
showed no evidence of significant tumor progression (Figure
5B), suggesting that some tumors may have prolonged
benefit from this combination.

To further examine the effects of single treatment
and combination treatment on tumor growth in mice, we
expressed firefly luciferase in GSC272 to monitor tumor
kinetics using bioluminescent imaging (Figure 5C and 5D).
IR resulted in a strong decrease in tumor volume;
however, tumor progression was eventually observed,
by bioluminescence, at later time points, which suggests
tumor recurrence. IR in combination with volasertib
significantly sensitized IR-mediated tumor growth
inhibition, with a significant delay in tumor volume
growth compared with IR treatment alone (P < 0.001).

Combination of volasertib and radiation
synergistically inhibits tumor cell proliferation,
induces DNA damage after radiation, and
induces apoptosis in vivo
Immunostaining of the proliferation marker
Ki-67 was performed to identity proliferating cells in the
xenografts subjected to different treatments. As shown
in Figure 6A, the Ki-67-positive proliferating tumor cell

Figure 4: Effects of PLK1 inhibition by volasertib and radiation on apoptosis induction, cell cycle arrest, and clonogenic
assay for self-renewal of GSCs. (A) Western blotting data showed prominent PARP cleavage in the combination treatment group

compared with the volasertib treatment alone group. γ-H2AX and cyclin B1 expression levels were higher in the combination treatment
group than in the volasertib-treatment alone group. (B) Flow cytometric assay of apoptosis by annexin V staining confirmed increased
apoptosis induction in response to combination treatment than to single treatment. (C) Colony-formation assay demonstrated that volasertib
combined with radiation had a synergistic effect on inhibiting colony formation in GSCs. Results are expressed as means ± SEM.
www.impactjournals.com/oncotarget

10502

Oncotarget

population was significantly inhibited by volasertib, IR,
and the combination compared with the control group.
Moreover, significant mitotic cell death, as indicated by
massive nuclear staining, was observed in the combination
group. To determine whether volasertib could enhance IRmediated DNA damage, γ-H2AX was evaluated 1 week
following IR. DNA damage was significantly higher in
the IR group compared with control and volasertib-treated
groups, and this IR-mediated DNA damage was enhanced
by treatment with volasertib. However, there was no

dramatic difference in p-HH3 staining among the groups
as shown in Figure 6A.
The aforementioned in vitro data suggest that the
cytotoxic effects of combined volasertib and IR were
synergistically mediated apoptosis induction; therefore, to
determine whether similar effects would be observed in
in vivo models, we assessed apoptosis staining by TUNEL.
As shown in Figure 6B and 6C, TUNEL staining revealed
significant apoptosis induction in the combination group
compared with control and single-treatment groups. This

Figure 5: The combination of volasertib (10 mg/kg) and radiation (10 Gy) inhibited tumor growth and prolonged
median survival in an intracranial mouse GSC xenograft model. (A) Kaplan-Meier curve from the GSC272 model showed

that the radiation group and combination group had significantly prolonged median survival compared with control and volasertib alone
(P < 0.001 versus control). Notably, the combination treatment group had dramatically extended median survival compared with radiation
treatment alone (P < 0.001 versus radiation), and the long-term survival of the combination group was 30% compared with 0% in other
groups. (B) H&E staining of brain after the mice were sacrificed at 104 days after implantation showed no evidence of significant tumor
progression suggesting that some tumors may have prolonged benefit from this combination. (C) Representative bioluminescent images of
the GSC272 intracranial mouse xenograft model and the normalized average radiance (photons/s/cm2/sr) with various treatments and time
points. (D) Radiation reduced tumor growth compared with control, which was further enhanced by combining radiation with volasertib
(P < 0.001 versus radiation). Results are expressed as means ± SEM. (E) A similar response was seen in the GSC23 intracranial xenograft
model, in which radiation treatment and combination treatment significantly prolonged median survival.
www.impactjournals.com/oncotarget
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pro-apoptotic effect of combined treatment correlated with
prolonged median survival.

after radiation and do not correlate to apoptotic genes Bcl2
in clonogenic survival assays [25]. However, our results
shows that in, in vivo xenograft models the combination of
volasertib and radiation significantly inhibited GSC tumor
growth and prolonged median survival when compared
with radiation alone. These differences could be attributed
to organ specific cellular properties and variation in cell
growth and culturing conditions. Here we show for the
first time to our knowledge that high expressions of antiapoptotic protein Bcl-xL was a biomarker highly correlated
with volasertib resistance.
The treatment of GBM remains challenging despite
meaningful progress, over the past two decades, in the
molecular treatment of many other cancers, such as lung
and breast. In recent years, significant progress in our
understanding of the molecular pathogenesis of GBM

DISCUSSION
Here, we show that PLK1 inhibitor volasertib
synergistically enhances radiation efficacy in vitro and
in vivo in GBM. The following lines of evidence support
this statement. First, volasertib inhibited the viability of
GSCs and induced G2/M arrest and apoptosis in a dose- and
time-dependent manner. Second, GSCs, arrested in M phase
by volasertib, were more sensitive to IR, as evidence by in
inducing G2/M arrest, synergism in inducing apoptosis and
inhibiting colony formation. Previous studies have shown
that E1A and Ras transformed p53 null and wild type mouse
embryonic fibroblasts do not undergo significant apoptosis

Figure 6: Combination of volasertib and radiation synergistically inhibits tumor cell proliferation, induces DNA
damage and apoptosis in vivo. (A) Immunohistochemical analysis of Ki-67, γ-H2AX, and p-HH3 in xenograft tumors that were treated
with volasertib alone, radiation alone, and volasertib combined with radiation compared with untreated mice. A significant reduction in Ki67 staining was observed in the volasertib, radiation, and combination treatment groups compared with control, indicating there were more
mitotic cell deaths. The DNA damage marker γ-H2AX was enhanced in the radiation treatment group and the combination treatment group
when the slides were stained the week following radiation. There were no significant p-HH3 changes among groups. (B) A TUNEL assay
was performed to measure apoptosis in brain sections from GSC xenograft mice, with TUNEL in red and DAPI in blue. Arrows indicate
examples of TUNEL-positive cells. (C) There were higher numbers of TUNEL-positive cells in the combined volasertib and radiation
treatment group than in the control, volasertib-treatment alone, or radiation-treatment alone group. (*P < 0.05, **P < 0.01).
www.impactjournals.com/oncotarget
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has been made [8, 26–28]. Extensive profiling of the
GBM genome has identified multiple activated signaling
pathways that play a central role in cancer cell growth,
survival, motility, and metabolism, which represent
potential therapeutic targets [8, 26–28]. However, the
development of targeted therapy is complicated by the
complexity and redundancy of these signaling pathways.
The presence of self-renewing GSCs is thought to
be responsible for tumor initiation, heterogeneity, and
resistance to standard therapies. These GSCs closely
resemble the parent tumor both genotypically and
phenotypically, thus making the use of GSCs a desirable
approach for developing more effective therapeutic
strategies. The Brain Tumor Center at MD Anderson
Cancer Center has been collecting GSCs from patient
tumor samples and profiling them by a number of “omics”
techniques [29, 30]. In this study, we used HTS to identify
the drug sensitivities of a panel of GSC lines to a panel
of compounds in PKIS, and we identified sensitivity of
GSCs to PLK1 inhibitors. Similar results were reported
by another group, who used high-content imaging-based
screening assays and who observed that GSCs were
acutely susceptible to proliferative disruption by PLK1
inhibitors [31].
PLKs are a group of highly conserved serine/
threonine kinases with various key regulatory functions
during cell cycle progression, and PLK1 is the best
characterized cancer target in the PLK family [10, 13, 16].
PLK1 is overexpressed in several tumor types, including
breast cancer, non-small cell lung cancer (NSCLC),
and colorectal cancer, and elevated PLK1 has also been
correlated with poor prognosis in NSCLC and breast
cancer patients [13, 32, 33]. Nonetheless, the promising
effects of PLK1 inhibition in GBM remain poorly
developed [23, 34, 35]. To further validate the HTS results,
we used volasertib to investigate the potential therapeutic
application of PLK1 inhibitors in GBM. Volasertib, a
second generation dihydropterinone derivative, is a potent
ATP-competitive selective inhibitor of PLK1, and it also
inhibits PLK2 and PLK3 [11]. It has demonstrated broad
antitumor activity with a high volume of distribution,
indicating good tissue penetration, and a long terminal
half-life in preclinical studies [36]. Several phase I, II, and
III clinical trials have evaluated the efficacy of volasertib
in treating leukemia, lung cancer, and pancreatic cancer
and have shown encouraging results [11, 12, 37–39].
However, few reports have considered the use of volasertib
in GBM. In the current study, we found that volasertib
potently inhibited the proliferation of a panel of GSC lines
with nanomolar IC50. Data from the RPPA studies, verified
with Western blotting, determined that high expression
of Bcl-xL was associated with resistance to volasertib
in the cell lines tested. Consistent with previous studies,
volasertib promoted mitotic exit delay, which resulted
in G2/M arrest and subsequent induction of apoptosis
[22, 23]. Loss of p53 and/or p21Cip1/CDKN1A renders cancer
www.impactjournals.com/oncotarget

cells susceptible to PLK1 inhibition [31, 40]. Further
studies will be necessary to determine if tumors with p53
mutations, loss of CDKN1A, or other molecular markers
are more susceptible to this combination strategy.
Acquired resistance to therapy is a common
problem in patients with GBM. Of the three main
therapies for GBM—surgical resection, radiation
therapy, and chemotherapy—radiation remains the most
relatively efficacious therapy for primary brain tumors
[1]. However, many patients have disease refractory to
radiation therapy, and this radioresistance ultimately
leads to tumor recurrence. Therefore, there is an urgent
need to develop strategies to radiosensitize GBM tumor
cells. Hence, we tested the efficacy of the combination
of volasertib with radiation in preclinical models, as a
prerequisite to future clinical studies. The in vitro data in
this study showed that the combination of volasertib with
radiation improved radiation efficacy in inhibiting colony
formation and inducing apoptosis. Here, we show, for the
first time, that combination treatment significantly delayed
tumor growth in mice implanted with GSC23 or GSC272,
and significantly prolonged median survival by inhibiting
tumor growth and inducing apoptosis.
One potential limitation of the current study is
that volasertib treatment alone showed no effects on
inhibiting in vivo tumor growth or prolonging median
survival. This may be attributed to poor biodistribution
of volasertib within the brain, due to a suboptimal dose
and/or a relatively intact blood-brain barrier. In the
limited amount of literature reporting on the use of PLK1
inhibitors, the PLK1 inhibitors with significant antitumor
effects in GBM have been GSK461364A at 100 mg/kg
[22] and BI2536 at 50 mg/kg [34]. The dose of volasertib
that we chose for this study, 10 mg/kg, may not have
been sufficient as a monotherapy in our complex in vivo
model. However, radiotherapy can increase blood-brain
barrier permeability and improve drug delivery to brain
tumors [41, 42]. Therefore, in our study, radiation therapy
may have increased the brain biodistribution of 10 mg/kg
volasertib, leading to synergistic enhancement in radiation
therapy-mediated tumor growth inhibition and median
survival prolongation. Moreover, microenvironmental
factors including hypoxia, molecular heterogeneity, and
tumor invasion may also limit the in vivo efficacy of
volasertib alone [2, 43]. Accordingly, we cannot exclude
the possibility that the beneficial effects of volasertib
observed in vitro might be less evident in vivo, and further
optimization of this combined approach is needed to fully
realize the benefit.
Taken together, the findings of our study both confirm
and expand on previous in vitro and in vivo studies by
demonstrating that volasertib inhibits tumor proliferation,
induces G2/M arrest, and induces apoptosis by sensitizing
GSCs to radiation to synergistically delay tumor growth
and prolong median survival. This study has convincingly
shown that targeting PLK1 with volasertib, in combination
10505
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with radiation therapy, may be a novel strategy to overcome
resistance in the treatment of patients with GBM. Additional
studies will be required to investigate the mechanisms of
the synergistic effect of this promising combination regimen
and to further optimize the safety, feasibility, and clinical
effectiveness of this therapy.

detachment solution (Sigma). Cells were collected,
washed with PBS, and fixed with ice-cold 70% ethanol
for at least 1 hour. Then, cells were washed twice in PBS,
treated for 30 minutes at 37°C with PI/RNase Staining
Buffer (BD Biosciences), and analyzed using a FACScan
flow cytometer (Becton-Dickinson) to determine subG1
(apoptosis), G1, S, and G2/M cell cycle distribution.
Apoptosis was detected using the BD Annexin V FITC
Assay on the BD FACSVerse System (BD Biosciences).

MATERIALS AND METHODS
GSC isolation and cell culture

Clonogenic formation assay

GSC lines were isolated from brain tumor specimens
at The University of Texas MD Anderson Cancer
Center, Houston, TX. The Institutional Review Board
of MD Anderson Cancer Center approved acquisition of
these cell lines from patients, who provided informed
consent. Glioma stem cell development is funded by
the MD Anderson Brain Cancer SPORE supported by
P50CA127001. GSCs were maintained in DMEM/F12
medium supplemented with B27 supplement (Invitrogen),
20 ng/ml epidermal growth factor (EGF), and 20 ng/ml
fibroblast growth factor (FGF) at 37°C in a humidified
atmosphere of 5% CO2 and 95% air [5, 30]. GSCs were
tested and authenticated by DNA typing at the MD
Anderson Cancer Center Cell Line Characterization Core
and were subsequently verified for our study.

For evaluation of clonogenic formation, posttreatment GSCs were seeded at 3–5 cells per well in
triplicate 96-well plates for 3 weeks [29]. Wells with
neurospheres (>100 micron M) were counted as positive
and wells without spheres as negative. The percentages of
positive neurospheres in each plate were compared among
different treatment groups.

Western blot analysis and reverse-phase protein
array (RPPA)
Cells were lysed in an ice-cold RIPA lysis buffer
containing a cocktail of proteinase inhibitors and
phosphatase inhibitors. The protein concentration in
the supernatant was determined using the BCA protein
assay (Pierce Chemical). Samples were subjected to 8%
to 15% SDS-PAGE, and the separated proteins were
electrophoretically transferred to PVDF membranes. Blots
were incubated with the primary antibodies, and then
incubated with horseradish peroxidase-linked secondary
anti-rabbit or anti-mouse antibodies (GE). GSC protein
lysate samples were probed with 279 validated primary
antibodies for the analysis at the MD Anderson Functional
Proteomics Reverse Phase Protein Array (RPPA) Core
facility. (https://www.mdanderson.org/education-andresearch/resources-for-professionals/scientific-resources/
core-facilities-and-services/functional-proteomics-rppacore/index.html).

High-throughput screening
GlaxoSmithKline provided the PKIS with 357
compounds, including the 21 most highly active
compounds. A panel of GSC cell lines, which have been
well characterized for their protein and gene expression,
was screened in 384-well plates at a density of 1000 cells/
well with 16 serially diluted drug concentrations. On the
same day, 50 nl of each compound was transferred into
cell wells using the Tecan Evo200 robotic system. Five
days after drug treatment, cell viability was determined by
using the CellTiter-Blue cell viability assay and compared
with values from vehicle control wells to calculate the
half-maximal inhibitory concentration, IC50. Each cell line
was screened in duplicate. The quality of the assay was
estimated by calculating a Z′-factor. Average Z′ value for
all screens was 0.7 ± 0.5. A separate set of compounds,
containing doxorubicin and molecularly targeted agents to
tumor growth factor beta (TGF-β), signal transducer and
activator of transcription 3 (STAT3), phosphoinositide
3-kinase (PI3K), and epidermal growth factor receptor
(EGFR), was used as the positive control plate to compare
drug efficacy.

Xenograft models and treatment
GSCs were intracranially implanted, using the guidescrew system, into 4- to 6-week-old female nude mice
[44]. One week after guide screw implantation, 500,000
cells were intracranially injected into each mouse, and the
mice were randomly distributed to receive different vehicle
control, volasertib (10 mg/kg), 2.5-Gy IR, or volasertib
(10 mg/kg) plus 2.5-Gy IR. A minimum of 10 mice was used
in each treatment group to generate survival curves. For
in vivo bioluminescent imaging, GSCs were engineered to
express luciferase by transducing GSCs with pCignal lentiCMV-luc viral particles (SABiosciences). Kinetics of tumor
growth was monitored by IVIS 200 system bioluminescent
imaging. Two weeks after GSC implantation and one week
before IR, volasertib (10 mg/kg) was administrated twice a

Cell cycle and apoptosis analysis by flow
cytometry
After drug treatment, GSCs were pelleted by
centrifugation and dissociated with Accutase cell
www.impactjournals.com/oncotarget
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week by oral gavage until the end of the experiment. The
radiation treatment involved four cycles of 2.5-Gy IR, on
four consecutive days. IR was delivered using a 60Co teletherapy unit and a custom gig with validated dosimetry.
Mice with neurological symptoms (i.e., hydrocephalus,
seizures, inactivity, and/or ataxia) or that were moribund
were euthanized. Brains were fixed in formalin, stained
with H&E to confirm the presence of tumor, and subjected
to immunohistochemical analysis. All animal procedures
were reviewed and approved by the Institutional Animal
Care and Use Committee at MD Anderson Cancer Center.

This work was supported by the Martha G.
Williams Memorial Brain Tumor Research Fund (JFD),
Defeat GBM Research Collaborative, a subsidiary of the
National Brain Tumor Society (JFD), and The University
of Texas MD Anderson Glioblastoma Moon Shots
Program (JFD). Glioma stem cell development is funded
by the MD Anderson Brain Cancer SPORE supported by
P50CA127001.
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